Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3857 results
FibroGen reports one-year data of FG-3019 in patients with Idiopathic Pulmonary Fibrosis
FibroGen has announced the presentation of the full data set from a clinical study of patients with idiopathic pulmonary fibrosis (IPF) treated for 48 weeks with the investigational drug FG-3019.
Drug Research > Drug Discovery & Development > News
Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint
By PBR Staff Writer
Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen.
Drug Research > Drug Discovery & Development > News
Boehringer, CureVac to develop next generation lung cancer immunotherapy
By PBR Staff Writer
Boehringer Ingelheim has entered into an exclusive global license and development agreement with CureVac to develop the latter's new investigational therapeutic mRNA vaccine CV9202 to treat lung cancer.
Drug Research > Drug Discovery & Development > News
Lupin and Merck Serono enter into strategic alliance
By PBR Staff Writer
Lupin and Merck Serono have entered into a strategic partnership to support the latter to broaden its general medicines portfolio in emerging markets.
Drug Research > Drug Discovery & Development > News
Cardiorentis announces €45m financing with HealthCare Royalty Partners
By PBR Staff Writer
Cardiorentis AG, a privately held biopharmaceutical company, announced that it has entered into a €45m financing agreement with HealthCare Royalty Partners (HC Royalty), a US based healthcare investment firm.
Drug Research > Drug Discovery & Development > News
Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study
By PBR Staff Writer
Glenmark Pharmaceuticals announced that its first in class Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India.
Drug Research > Drug Discovery & Development > News
Boehringer, Eli Lilly present results from Phase III study of empagliflozin/linagliptin combination tablet for type 2 diabetes
By PBR Staff Writer
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were previously untreated.
Drug Research > Drug Discovery & Development > News
Alnylam adds HDP treatment ALN-AGT to strengthen pipeline
By PBR Staff Writer
US-based biopharmaceutical firm Alnylam Pharmaceuticals has strengthened its pipeline with the addition of ALN-AGT, a subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT) indicated to treat hypertensive disorders of pregnancy (HDP), including preeclampsia.
Drug Research > Drug Discovery & Development > News
Cellerant gets $47.5m contract to support development of CLT-008
By PBR Staff Writer
US-based biotechnology firm Cellerant Therapeutics has received $47.5m contract under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) to support the continued advanced development of CLT-008.
Drug Research > Drug Discovery & Development > News
Abbvie reports positive Phase III trial results of Humira in hidradenitis suppurativa patients
By PBR Staff Writer
US-based biopharmaceutical firm AbbVie has reported positive results from a Phase III pivotal trial, which was designed to evaluate the investigational use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS).
Drug Research > Drug Discovery & Development > News
New medicines in development give hope to patients with HIV/AIDS
America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Drug Research > Drug Discovery & Development > News
ViaCyte gets $16.6m grant from CIRM to develop VC-01 diabetes therapy candidate
By PBR Staff Writer
US-based regenerative medicine firm ViaCyte has received a $16.6m Accelerated Development Pathway grant from the California Institute for Regenerative Medicine (CIRM) to develop a stem cell-derived islet replacement therapy called VC-01 to treat patients with type 1 diabetes.
Drug Research > Drug Discovery & Development > News
SRI International, Nobelpharma ink deal to develop endometriosis drug
By PBR Staff Writer
US-based nonprofit research institute SRI International and Japanese pharmaceutical firm Nobelpharma have entered into a licensing agreement to test SR16234 for the treatment of endometriosis, a chronic disease.
Drug Research > Drug Discovery & Development > News
Critical Outcome Technologies, UT MD Anderson sign letter of ontent for Phase 1 development of COTI-2
Critical Outcome Technologies, the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a letter of intent ("LOI") with The University of Texas MD Anderson Cancer Center in Houston ("MD Anderson"), for the Phase 1 clinical development of the Company's lead cancer drug candidate, COTI-2, in gynecological cancers.
Drug Research > Drug Discovery & Development > News
PharmAthene, Nanotherapeutics to advance biodefense programs
PharmAthene and Nanotherapeutics, a privately-held biopharmaceutical company, have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market.
Drug Research > Drug Discovery & Development > News
91-105 of 3857 results